What is it about?
Thymosin α1 is an immunoregulatory medication, that has recently been indicated to be an effective therapeutic agent for inpatient management of lymphocytopenia and T cell exhaustion caused by COVID-19.
Featured Image
Why is it important?
The elderly are perhaps the most vulnerable community, who stand at the pinnacle of morbidity and mortality rates due to contracting severe forms of COVID-19. Lymphocytopenia is a laboratory finding associated with moderate to critical cases of COVID-19, that should be treated simultaneously.
Perspectives
This article is important in that it marks the beginning of my professional academic career as a researcher.
Milad Shirvaliloo
Tabriz University of Medical Sciences
Read the Original
This page is a summary of: Thymosin α1; Potential Therapeutic Implications of an Immunoregulatory Drug in the Treatment of Lymphocytopenia Associated with COVID-19, Current Immunology Reviews, December 2020, Bentham Science Publishers,
DOI: 10.2174/1573395516999201111163304.
You can read the full text:
Contributors
The following have contributed to this page
